Greg Jicha News Today

On July 6, 2023, the U.S. Food and Drug Administration granted full approval to lecanemab, marketed as Leqembi, for the treatment of Alzheimer's disease.

The FDAs landmark decision makes Leqembi more accessible for about 1 million patients across the country.

A Kentucky patient in clinical trials of a 'promising' new Alzheimer's drug at UK's Sanders-Brown Center on Aging says the FDA's recent full approval is among the reasons he participated.

A key antibody treatment in the fight against Alzheimer’s disease, which the University of Kentucky has been studying, just got a full green light from the U.S. Food and Drug

On Borkowski made quite an impression in high school when he planted a kiss on a pretty, blonde-haired girl who would later become his wife.

By Dr. Greg JichaUniversity of KentuckyHave you ever been ready to head out the door but can’t seem to remember where you put your keys? Or have you been standing in the grocery store trying t

Greg Jicha, M.D., Ph.D, assistant professor of neurology, University of Kentucky College of Medicine and UK Sanders-Brown Center on Aging and Alzheimer’s Disease Center, discusses keeping your mind sharp while aging in this week's health column.

The annual "Facts and Figures" report shows more Americans are being diagnosed with the disease and more needs to be done to stop it.

Alzheimer's researchers hope to learn more about the long-term benefits of lecanemab, an antibody that targets amyloid plaques from the brain

The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of a promising drug known as lecanemab. Just a few weeks ago the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease. This represents an important advancement in the ongoing fight to effectively treat Alzheimer’s disease, and UK’s Sanders-Brown Center on Aging is on the forefro...